The industry’s ten-point framework scopes out specific areas of action including innovation, access and affordability of drugs, prevention and health education. It also underscores the essential role of partnerships and dialogue in implementing the framework.
The framework confirms the industry’s crucial role in continued investment in R&D programmes to develop drugs for the prevention and treatment of non-communicable disease, with over 1,500 products in the pipeline currently. It also commits the industry to target its innovation towards...
This page requires a Science|Business Network Membership
This page is available to Science|Business Network Members only. If you are already a member then please log in (above).
Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.
Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.
Be where innovation begins – become a member. Click here to learn more.